S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44

Intersect ENT (XENT) Stock Forecast, Price & News

0.00 (0.00%)
(As of 05/13/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Average Volume
351,526 shs
Market Capitalization
$954.91 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive XENT News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.

Intersect ENT logo

About Intersect ENT

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$106.75 million
Book Value
($2.78) per share


Net Income
$-159.63 million
Net Margins
Pretax Margin




Free Float
Market Cap
$954.91 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.59 out of 5 stars

Medical Sector

983rd out of 1,423 stocks

Surgical & Medical Instruments Industry

104th out of 138 stocks

Analyst Opinion: 1.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Intersect ENT (NASDAQ:XENT) Frequently Asked Questions

Is Intersect ENT a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Intersect ENT stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XENT, but not buy additional shares or sell existing shares.
View analyst ratings for Intersect ENT
or view top-rated stocks.

When is Intersect ENT's next earnings date?

Intersect ENT is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Intersect ENT

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) posted its quarterly earnings results on Tuesday, March, 8th. The medical equipment provider reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.40. The medical equipment provider had revenue of $30.67 million for the quarter, compared to analysts' expectations of $37.43 million. Intersect ENT had a negative trailing twelve-month return on equity of 709.52% and a negative net margin of 161.94%.
View Intersect ENT's earnings history

What price target have analysts set for XENT?

3 brokerages have issued 1 year target prices for Intersect ENT's shares. Their forecasts range from $28.25 to $28.30. On average, they expect Intersect ENT's stock price to reach $28.28 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price.
View analysts' price targets for Intersect ENT
or view top-rated stocks among Wall Street analysts.

Who are Intersect ENT's key executives?
Intersect ENT's management team includes the following people:
  • Mr. Thomas A. West, Pres, CEO & Director (Age 58, Pay $908.97k)
  • Mr. Richard A. Meier, Exec. VP & CFO (Age 62, Pay $621.76k)
  • Mr. Patrick A. Broderick, Exec. VP, Gen. Counsel & Corp. Sec. (Age 63, Pay $138.46k)
  • Ms. Reyna M. Fernandez, Chief Human Resource Officer
  • Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 58)
What is Thomas West's approval rating as Intersect ENT's CEO?

7 employees have rated Intersect ENT CEO Thomas West on Glassdoor.com. Thomas West has an approval rating of 41% among Intersect ENT's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Intersect ENT own?
What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Who are Intersect ENT's major shareholders?

Intersect ENT's stock is owned by a variety of retail and institutional investors. Top institutional investors include Versor Investments LP (9.84%), BlackRock Inc. (7.78%), Vanguard Group Inc. (5.14%), Alpine Associates Management Inc. (4.09%), State Street Corp (2.48%) and Goldman Sachs Group Inc. (2.20%).
View institutional ownership trends for Intersect ENT

Which major investors are selling Intersect ENT stock?

XENT stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, State Street Corp, Citigroup Inc., Vanguard Group Inc., Havens Advisors LLC, Alpine Associates Management Inc., Mint Tower Capital Management B.V., and Russell Investments Group Ltd..
View insider buying and selling activity for Intersect ENT
or view top insider-selling stocks.

Which major investors are buying Intersect ENT stock?

XENT stock was bought by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, Candriam Luxembourg S.C.A., Prelude Capital Management LLC, Hsbc Holdings PLC, Versor Investments LP, Chicago Capital Management LLC, Goldman Sachs Group Inc., and Qube Research & Technologies Ltd.
View insider buying and selling activity for Intersect ENT
or or view top insider-buying stocks.

How do I buy shares of Intersect ENT?

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $28.24.

How much money does Intersect ENT make?

Intersect ENT has a market capitalization of $954.91 million and generates $106.75 million in revenue each year. The medical equipment provider earns $-159.63 million in net income (profit) each year or ($4.790010) on an earnings per share basis.

How many employees does Intersect ENT have?

Intersect ENT employs 433 workers across the globe.

What is Intersect ENT's official website?

The official website for Intersect ENT is www.intersectent.com.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at (650) 641-2100, via email at [email protected], or via fax at 866-736-1251.

This page was last updated on 5/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.